search
Back to results

Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis

Primary Purpose

Spondylitis, Tuberculosis

Status
Not yet recruiting
Phase
Phase 2
Locations
Indonesia
Study Type
Interventional
Intervention
400 IU
5000 IU
10000 IU
Fixed Drug Combination
Sponsored by
Hasanuddin University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spondylitis focused on measuring Vitamin D, Spondylitis Tuberculosis, Clinical Improvement, Toll-Like Receptor

Eligibility Criteria

19 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosed as Spondylitis Tuberculosis (Clinically and Laboratory confirmed)
  2. Level of Total Vitamin D <50 nmol/L at baseline

Exclusion Criteria:

  1. Participants with pulmonary tuberculosis or other extrapulmonary tuberculosis
  2. Participants with osteoporosis, malignancy, cardiovascular disease, diabetes mellitus, and autoimmune disease
  3. Participants with liver and kidney dysfunction
  4. Participants who received Vitamin D prior to enrollment

Sites / Locations

  • Wahidin Sudirohusodo General Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Control Group

Moderate Dose

High Dose

Arm Description

This group will be given standardized tuberculosis drug with 400 IU of oral Vitamin D3

This group will be given standardized tuberculosis drug with 5000 IU of oral Vitamin D3

This group will be given standardized tuberculosis drug with 10000 IU of oral Vitamin D3

Outcomes

Primary Outcome Measures

The Oswestry Disability Index
This questionnaire assess the impact of back pain to the daily life. This questionnaire contains 10 6-likert scale questions with the score ranging from 0-5 for each questions. The total score ranging from 0-50. The index is calculated as raw score per total score and presented as percentage. Below is the classification and interpretation of the score: 0% -20%: Minimal disability 21%-40%: Moderate Disability 41%-60%: Severe Disability 61%-80%: Crippling back pain 81%-100%: These patients are either bed-bound or have an exaggeration of their symptoms
The Visual Analogue Scale
This scale represent the pain according to a visual score measured using 10-likert scale. Maximum number indicates extreme/intractable pain
Toll-Like Receptor 2 (TLR-2)
The level of TLR-2 in blood measured using ELISA
Toll-Like Receptor 4 (TLR-2)
The level of TLR-4 in blood measured using ELISA

Secondary Outcome Measures

Full Information

First Posted
May 11, 2022
Last Updated
May 11, 2022
Sponsor
Hasanuddin University
search

1. Study Identification

Unique Protocol Identification Number
NCT05376189
Brief Title
Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis
Official Title
The Effect of Vitamin D Supplementation on Toll-Like Receptor (TLR) 2, 4, and Clinical Outcomes of Spondylitis Tuberculosis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2022 (Anticipated)
Primary Completion Date
December 30, 2022 (Anticipated)
Study Completion Date
February 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hasanuddin University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background : The toll-like receptor is an essential receptor that stimulates the innate immunity response. In tuberculosis, toll-like receptors, particularly the TLR-2, and TLR-4 are crucial in recognizing various ligands with a lipoprotein structure in the bacilli. Vitamin D deficiency leads to lower expression of these receptors, Hence the immune response against Mycobacterium tuberculosis will be altered. Various studies addressed the importance of vitamin D supplementation in pulmonary tuberculosis but the effect of vitamin D in extrapulmonary tuberculosis, particularly spondylitis tuberculosis is not sufficiently identified. Objectives: To assess the effect of oral vitamin D supplementation on the expression of TLR-2, TLR-4, and clinical outcomes in spondylitis tuberculosis patients. Methodology: This study proposes a randomized clinical trial of oral vitamin D supplementation in spondylitis tuberculosis patients. Multiple arms will be established with different doses and control groups. The outcome of interest includes the clinical outcomes, the expression of TLR-2, and TLR 4 Hypothesis : It is assumed that oral supplementation of Vitamin D will increase the activation of Toll-Like Receptors and improves the clinical condition of Spondylitis Tuberculosis patients
Detailed Description
Target population: Patients with spondylitis tuberculosis without the involvement of lung and other extrapulmonary infection Design: Randomized Clinical Trial with 3 arms Primary Intervention: Standardized Tuberculosis treatment with oral Vitamin D3 Supplementation daily for 8 weeks Outcome: Toll-Like Receptors (TLR) 2 and 4 levels from the blood sample, measured using Enzyme-linked Immunoassay (ELISA). Clinical Evaluation with Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI). The outcomes will be measured three times at 4-week intervals (baseline, week 4, and week 8) Sample Size and Recruitment Participants will be recruited from hospitals and allocated by simple randomization Biological Sample and consent Participants are aware that clinical data collection and biological samples will be obtained by researchers. This is mentioned in informed consent prior to study recruitment Blood sample will be obtained in a standardized phlebotomy procedure and will not be retained after the study is finish. Hypothesis Sample Size Calculation: The trial will be designed to compare 2 experimental treatments to a shared control arm. The sample size was estimated based on the mathematical calculation by a study below Grayling, M.J et al With the assumption of : K=2 experimental treatments will be included in the trial. A significance level of α=0.05 will be used, in combination with no multiple comparison correction. The event rate in the control arm will be assumed to be: λ0=5. The marginal power for each null hypothesis will be controlled to level 1-β=0.8 under each of their respective least favorable configurations. The interesting and uninteresting treatment effects will be δ1=2.5 and δ0=0 respectively. The target allocation to each of the experimental arms will be the same as the control arm. The sample size in each arm will not be required to be an integer. Hence total sample should be 37 participants Proposed Statistical Analysis Descriptive Statistics Bivariate Analysis The study will apply intention-to-treat analysis Linear Mixed model to measure the effect of intervention adjusted by fixed and random factors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spondylitis, Tuberculosis
Keywords
Vitamin D, Spondylitis Tuberculosis, Clinical Improvement, Toll-Like Receptor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
This study involves three arms intervention consists of one control group with standardized tuberculosis treatment, and two intervention groups with different level of vitamin D supplementation;
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participants will be masked from the intervention by giving a similar vitamin D preparation in each group. Investigator, Care Provider, and Outcome Assessor are blinded from allocation and only the Allocator knows the participants assigned groups
Allocation
Randomized
Enrollment
37 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
This group will be given standardized tuberculosis drug with 400 IU of oral Vitamin D3
Arm Title
Moderate Dose
Arm Type
Experimental
Arm Description
This group will be given standardized tuberculosis drug with 5000 IU of oral Vitamin D3
Arm Title
High Dose
Arm Type
Experimental
Arm Description
This group will be given standardized tuberculosis drug with 10000 IU of oral Vitamin D3
Intervention Type
Dietary Supplement
Intervention Name(s)
400 IU
Other Intervention Name(s)
Low Dose Vitamin D3
Intervention Description
An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
5000 IU
Other Intervention Name(s)
Moderate Dose Vitamin D3
Intervention Description
An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
10000 IU
Other Intervention Name(s)
High Dose Vitamin D3
Intervention Description
An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
Intervention Type
Drug
Intervention Name(s)
Fixed Drug Combination
Other Intervention Name(s)
Tuberculosis Regimen
Intervention Description
Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
Primary Outcome Measure Information:
Title
The Oswestry Disability Index
Description
This questionnaire assess the impact of back pain to the daily life. This questionnaire contains 10 6-likert scale questions with the score ranging from 0-5 for each questions. The total score ranging from 0-50. The index is calculated as raw score per total score and presented as percentage. Below is the classification and interpretation of the score: 0% -20%: Minimal disability 21%-40%: Moderate Disability 41%-60%: Severe Disability 61%-80%: Crippling back pain 81%-100%: These patients are either bed-bound or have an exaggeration of their symptoms
Time Frame
Changes of Score from Baseline to 8 weeks
Title
The Visual Analogue Scale
Description
This scale represent the pain according to a visual score measured using 10-likert scale. Maximum number indicates extreme/intractable pain
Time Frame
Changes of Score from Baseline to 8 weeks
Title
Toll-Like Receptor 2 (TLR-2)
Description
The level of TLR-2 in blood measured using ELISA
Time Frame
Changes of TLR-2 level from Baseline to 8 weeks
Title
Toll-Like Receptor 4 (TLR-2)
Description
The level of TLR-4 in blood measured using ELISA
Time Frame
Changes of TLR-4 level from Baseline to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed as Spondylitis Tuberculosis (Clinically and Laboratory confirmed) Level of Total Vitamin D <50 nmol/L at baseline Exclusion Criteria: Participants with pulmonary tuberculosis or other extrapulmonary tuberculosis Participants with osteoporosis, malignancy, cardiovascular disease, diabetes mellitus, and autoimmune disease Participants with liver and kidney dysfunction Participants who received Vitamin D prior to enrollment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jainal Arifin, MD
Phone
+6281144422666
Email
ia.jenal@yahoo.co.id
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jainal Arifin, MD
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nasrum Massi, MD. Ph.D
Organizational Affiliation
Hasanuddin University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Firdaus Hamid, MD. Ph.D
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andi Alfian Zainuddin, MD. Ph.D
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wahidin Sudirohusodo General Hospital
City
Makassar
State/Province
South Sulawesi
ZIP/Postal Code
76124
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jainal Arifin, MD
Phone
+628114442666
Email
ia.jenal@yahoo.co.id
First Name & Middle Initial & Last Name & Degree
Jainal Arifin, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
As the data is confidential. The data sharing will be granted by investigator upon request
Citations:
PubMed Identifier
32005187
Citation
Grayling MJ, Wason JM. A web application for the design of multi-arm clinical trials. BMC Cancer. 2020 Jan 31;20(1):80. doi: 10.1186/s12885-020-6525-0.
Results Reference
background
PubMed Identifier
28629765
Citation
Tang L, Liu S, Bao YC, Gao RX, Han CF, Sun XC, Zhang WL, Feng SQ. Study on the relationship between vitamin D deficiency and susceptibility to spinal tuberculosis. Int J Surg. 2017 Aug;44:99-103. doi: 10.1016/j.ijsu.2017.05.077. Epub 2017 Jun 16.
Results Reference
background
PubMed Identifier
27124026
Citation
Panwar A, Garg RK, Malhotra HS, Jain A, Singh AK, Prakash S, Kumar N, Garg R, Mahdi AA, Verma R, Sharma PK. 25-Hydroxy Vitamin D, Vitamin D Receptor and Toll-like Receptor 2 Polymorphisms in Spinal Tuberculosis: A Case-Control Study. Medicine (Baltimore). 2016 Apr;95(17):e3418. doi: 10.1097/MD.0000000000003418.
Results Reference
background
PubMed Identifier
23875738
Citation
Ojaimi S, Skinner NA, Strauss BJ, Sundararajan V, Woolley I, Visvanathan K. Vitamin D deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study. J Transl Med. 2013 Jul 22;11:176. doi: 10.1186/1479-5876-11-176.
Results Reference
background
Citation
Yu, Fang & Cailiang, Shen. (2019). Effect of vitamin D combined with anti-tuberculosis drugs on serum IL-1β, IFN-γ and TH17 cell-associated cytokines for the management of spinal tuberculosis. Tropical Journal of Pharmaceutical Research. 18. 1141-1147. 10.4314/tjpr.v18i5.32.
Results Reference
background

Learn more about this trial

Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis

We'll reach out to this number within 24 hrs